JP4637491B2 - Antiallergic composition - Google Patents
Antiallergic composition Download PDFInfo
- Publication number
- JP4637491B2 JP4637491B2 JP2004056862A JP2004056862A JP4637491B2 JP 4637491 B2 JP4637491 B2 JP 4637491B2 JP 2004056862 A JP2004056862 A JP 2004056862A JP 2004056862 A JP2004056862 A JP 2004056862A JP 4637491 B2 JP4637491 B2 JP 4637491B2
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- composition
- fermentation
- antiallergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、抗アレルギー性組成物、美白組成物及び該美白組成物を含有する化粧品に関する。更に詳しくは、豆類、ルイボス茶、又はバラを原料とし、この原料を発酵して得られる乳酸菌発酵抽出物を含有する抗アレルギー性組成物、美白組成物及び該美白組成物を含有する化粧品、並びに上記抗アレルギー性組成物又は上記美白組成物を含有する飲食品に関する。 The present invention relates to an antiallergic composition, a whitening composition, and a cosmetic containing the whitening composition. More specifically, an antiallergic composition containing a fermented extract of lactic acid bacteria obtained by fermenting beans, rooibos tea, or rose and fermenting the raw material, a whitening composition, and a cosmetic containing the whitening composition, and It is related with the food-drinks containing the said antiallergic composition or the said whitening composition.
本来、生体は体内に侵入した病原菌等の異物から身体を守る免疫機能を備えている。そして、体内に侵入した異物に対して過剰な免疫反応を起こし、身体に有害な形で現れる場合の一つがアレルギーである。アレルギーはプロセスによってＩ〜ＩＶ型に分類されるが、このうちＩ型のアレルギーを即時型といい、免疫グロブリン抗体のうちのＩｇＥ抗体と抗原の反応が引き金になって起こる。詳しく言えば、体内にカビ、花粉等の抗原が侵入すると、これに対する特異的な抗体であるＩｇＥ抗体が作られ、このＩｇＥ抗体のＦｃ部分が肥満細胞や好塩基球表面のＩｇＥレセプター結合に付着する（ヒトＩｇＥ−ＩｇＥレセプター結合）。そして、再び同一の抗原が体内に侵入すると、これが細胞表面のＩｇＥ抗体のＦａｂ部分にある抗原結合基と結合し、その結果、数個のＩｇＥを橋渡しする形となる。かかる橋渡しにより刺激された肥満細胞等から、ヒスタミン、ロイコトリエン等の種々のケミカルメディエーターが放出され、これらの働きによりアレルギーを引き起こす。このようなアレルギーによって引き起こされるアレルギー疾患の代表的なものには、花粉症、蕁麻疹、アトピー性皮膚炎及び気管支喘息等がある。そして、今日、これらのアレルギー疾患に苦しむ人々の数は増加傾向にあり、その予防方法及び改善方法が社会で注目されている。 The living body originally has an immune function that protects the body from foreign substances such as pathogenic bacteria that have entered the body. One of the cases where an excessive immune reaction is caused to a foreign substance that has entered the body and appears in a harmful form to the body is allergy. Allergies are classified into types I to IV depending on the process. Of these, type I allergies are called immediate types, and are triggered by the reaction between IgE antibodies of immunoglobulin antibodies and antigens. Specifically, when an antigen such as mold or pollen enters the body, an IgE antibody that is a specific antibody against the antigen is produced, and the Fc portion of this IgE antibody adheres to the IgE receptor binding on the surface of mast cells or basophils. (Human IgE-IgE receptor binding). When the same antigen enters the body again, it binds to the antigen-binding group in the Fab part of the IgE antibody on the cell surface, and as a result, several IgEs are bridged. Various chemical mediators such as histamine and leukotriene are released from mast cells and the like stimulated by the bridge, and allergies are caused by these functions. Representative examples of allergic diseases caused by such allergies include hay fever, urticaria, atopic dermatitis and bronchial asthma. Today, the number of people suffering from these allergic diseases is on the rise, and their prevention and improvement methods are attracting attention in society.
従来より、かかるアレルギー疾患に適用される化合物が各種報告されているが、そのほとんどが合成医薬品である。例えば、クロモグリク酸ナトリウム、トラニラスト、副腎皮質コルチコステロイド（プレドニゾロン等）、テオフィリン、マレイン酸クロルフェニラミン、塩酸ジフェンヒドラミン、及び塩酸シプロヘプタジン等が現在、アレルギー疾患の治療に用いられている。しかし、このような合成医薬品にはいずれも眠気等の副作用がある点で問題がある。また、従来の抗アレルギー化合物は、テオフィリンやβ２受容体作用薬（塩酸プロカテロール、サルブタモール等）のように、発作後の症状改善を目的としたり、あるいは、抗ヒスタミンＨ１薬（マレイン酸クロルフェニラミン、塩酸ジフェンヒドラミン、塩酸シプロヘプタジン等）やプランカルストのように、肥満細胞や好塩基球から放出されるケミカルメディエーターの作用に拮抗するものが中心である。アレルギー疾患の予防という観点から見れば、肥満細胞や好塩基球からケミカルメディエーターが放出された後、それにより引き起こされる反応を抑えるより、むしろ、それ以前のＩｇＥ−ＩｇＥレセプター結合反応や、ケミカルメディエーターの放出を抑制する作用を有することが好ましい。このような観点から、生体内において比較的安全であると共に、ケミカルメディエーターが放出される前の段階の反応を抑制し、アレルギー性疾患の予防に好適な抗アレルギー剤の開発が求められている。そして、特許文献１には、バラ抽出物が、ＩｇＥ−ＩｇＥレセプター結合反応を阻害し、抗アレルギー作用を奏することが記載されており、特許文献２には、バラ抽出物を発酵させて得られるバラ発酵抽出物が、抗アレルギー作用に優れていることが記載されている。 Conventionally, various compounds applied to such allergic diseases have been reported, most of which are synthetic drugs. For example, sodium cromoglycate, tranilast, corticosteroids (such as prednisolone), theophylline, chlorpheniramine maleate, diphenhydramine hydrochloride, cyproheptadine hydrochloride, and the like are currently used for the treatment of allergic diseases. However, all such synthetic drugs have problems in that they have side effects such as sleepiness. In addition, conventional antiallergic compounds, such as theophylline and β2 receptor agonists (procaterol hydrochloride, salbutamol, etc.), are intended to improve symptoms after seizures, or antihistamine H1 drugs (chlorpheniramine maleate, Mainly those that antagonize the action of chemical mediators released from mast cells and basophils, such as diphenhydramine hydrochloride, cyproheptadine hydrochloride, and plankalst. From the viewpoint of prevention of allergic diseases, rather than suppressing the reaction caused by the release of chemical mediators from mast cells and basophils, rather than suppressing the reaction caused by that, the previous IgE-IgE receptor binding reaction, It preferably has an action of suppressing release. From such a point of view, development of an antiallergic agent suitable for the prevention of allergic diseases is desired, which is relatively safe in vivo and suppresses the reaction at the stage before chemical mediators are released. Patent Document 1 describes that the rose extract inhibits the IgE-IgE receptor binding reaction and exhibits an antiallergic effect, and Patent Document 2 is obtained by fermenting the rose extract. It is described that the rose fermentation extract is excellent in antiallergic action.
また、近年、オゾンホールの拡大に伴い、地上へ到達する紫外線量の増加が懸念されている。紫外線により惹起される皮膚への悪影響、即ち、「くすみ」や「しみ」は、紫外線がメラノサイト（メラニンを合成する細胞）を活性化することにより、メラニン色素の生成が増加し、それが表皮に蓄積することにより起こる。即ち、メラノサイト内でチロシンにチロシナーゼが活性作用して、チロシンが酸化され、ドーパ、ドーパキノンに変換され、更に自動酸化等を経て、最終的にメラニン色素になる。このように生成されたメラニンが角質層に達し、このメラニンに紫外線が照射されると、既存のメラニンが酸化され、一時的に黒くなることも報告されている。 In recent years, with the expansion of the ozone hole, there is a concern about an increase in the amount of ultraviolet rays reaching the ground. The adverse effects on the skin caused by ultraviolet rays, ie “dullness” and “stains”, are caused by the fact that ultraviolet rays activate melanocytes (cells that synthesize melanin), which increases the production of melanin pigments, It happens by accumulating. That is, tyrosinase acts on tyrosine in melanocytes, and tyrosine is oxidized and converted into dopa and dopaquinone, and further undergoes auto-oxidation and the like, and finally becomes a melanin pigment. It has also been reported that when the melanin thus generated reaches the stratum corneum and the melanin is irradiated with ultraviolet rays, the existing melanin is oxidized and temporarily becomes black.
上記観点から従来より、美白を目的とした素材の開発、検討がなされてきている。従来、かかる美白等を目的とした化粧品等では、主に化学物質を配合することが多いが、使用者によっては肌に合わないこともあり、かぶれや痒みの原因となることがある。そこで、人工の化学物質と比べて安全な機能性素材として、植物等の天然物由来の抗チロシナーゼ活性作用及びメラニン色素生成抑制作用を有する物質が注目を集めている。そして、特許文献３には、米を乳酸菌で発酵して得られる発酵米が、顕著な美白・美肌化作用と髪質改善作用を示し、それら美粧効果を発現せしめるための配合剤としても有用であることが記載されている。更に、特許文献４及び５には、ヤシ科ココヤシ属植物の抽出物を乳酸菌類で発酵して得られる発酵代謝物、及びマメ科植物抽出物の乳酸菌類発酵物がチロシナーゼ活性を有意に抑え、美白効果を有することが記載されている。更に、特許文献６には、ルイボス茶の抽出物が美白効果を有することが記載されている。 From the above viewpoint, development and examination of materials aiming at whitening have been made. Conventionally, cosmetics for the purpose of whitening and the like often contain chemical substances mainly, but depending on the user, they may not fit the skin and may cause irritation and itching. Therefore, substances having an anti-tyrosinase activity action and a melanin pigment production inhibitory action derived from natural products such as plants have attracted attention as safer functional materials than artificial chemical substances. Patent Document 3 discloses that fermented rice obtained by fermenting rice with lactic acid bacteria exhibits remarkable whitening / skinning action and hair quality improving action, and is also useful as a compounding agent for developing these cosmetic effects. It is described that there is. Furthermore, in Patent Documents 4 and 5, a fermented metabolite obtained by fermenting an extract of a coconut palm genus plant with lactic acid bacteria, and a lactic acid bacteria fermented product of a leguminous plant extract significantly suppresses tyrosinase activity, It describes that it has a whitening effect. Furthermore, Patent Document 6 describes that rooibos tea extract has a whitening effect.
本発明は、上記現状に鑑みてなされたものであり、豆類、ルイボス茶、又はバラを原料とし、この原料を発酵して得られる乳酸菌発酵抽出物を含有する抗アレルギー性組成物、美白組成物及び該美白組成物を含有する化粧品、並びに上記抗アレルギー性組成物又は上記美白組成物を含有する飲食品を提供することを目的とする。 The present invention has been made in view of the above-described situation, and uses anti-allergic compositions and whitening compositions containing fermented lactic acid bacteria obtained by fermenting beans, rooibos tea, or rose as raw materials. And a cosmetic containing the whitening composition, and a food or drink containing the antiallergic composition or the whitening composition.
本発明者等は、上記の課題を解決すべく検討を重ねた結果、大豆、小豆等の豆類、ルイボス茶、又はバラを原料とし、この原料を発酵して得られる乳酸菌発酵抽出物とすることにより、単なる抽出物と比べて、抗アレルギー作用及び美白作用を更に向上させることができることを見出して本発明を完成するに至った。 As a result of repeated studies to solve the above problems, the present inventors made beans such as soybeans, red beans, rooibos tea, or roses as raw materials, and made lactic acid bacteria fermentation extracts obtained by fermenting these raw materials. As a result, it was found that the antiallergic action and whitening action can be further improved as compared with a simple extract, and the present invention has been completed.
本発明は以下に示す通りである。
〔１〕小豆及びルイボス茶のうちの少なくとも１つを含む培地に乳酸菌を接種し、発酵培養して得られた乳酸菌発酵組成物を含有することを特徴とする抗アレルギー用組成物。
〔２〕上記乳酸菌がラクトバチルス属、ラクトコッカス属、及びロイコノストック属に属する乳酸菌から選ばれる少なくとも１種である上記〔１〕記載の抗アレルギー用組成物。
〔３〕上記乳酸菌が、Lactobacillus brevis、Lactobacillus casei subsp.casei、Lactococcus lactis subsp.hordniae、及びLeuconostoc mesenteroides subsp.mesenteroidesから選ばれる少なくとも１種である上記〔１〕記載の抗アレルギー用組成物。
〔４〕ルイボス茶を含む培地に乳酸菌を接種する上記〔１〕乃至〔３〕のいずれかに記載の抗アレルギー用組成物。
The present invention is as follows.
[1] red beans and lactic acid bacteria were inoculated into a medium containing at least one of rooibos tea, antiallergic composition characterized by containing a lactic acid bacterium fermented composition obtained by fermentation culture.
[2] the lactic acid bacteria Lactobacillus, Lactococcus, and Leuconostoc above is at least one selected from the lactic acid bacterium belonging to the stock genus [1] antiallergic composition.
[3] the lactic acid bacterium, Lactobacillus brevis, Lactobacillus casei subsp.casei, Lactococcus lactis subsp.hordniae, and Leuconostoc mesenteroides is at least one selected from subsp.mesenteroides above [1] antiallergic composition.
[4] The antiallergic composition according to any one of [1] to [3], wherein a medium containing rooibos tea is inoculated with lactic acid bacteria .
本発明の抗アレルギー性組成物及び美白組成物は、豆類、ルイボス茶、又はバラを原料とし、これを乳酸菌で発酵して得られる乳酸菌発酵組成物を含有することにより、優れた抗アレルギー作用及び美白効果を奏する。また、本発明の化粧品は、本発明の美白組成物を含有することにより、優れた美白効果を奏する。更に、本発明の飲食品は、日常的に摂取することができ、その結果、日常的に抗アレルギー及び美白効果を実現することができる。 The anti-allergic composition and the whitening composition of the present invention contain a lactic acid bacterium fermentation composition obtained by fermenting beans, rooibos tea, or rose with a lactic acid bacterium as a raw material. Provides a whitening effect. Moreover, the cosmetics of this invention have the outstanding whitening effect by containing the whitening composition of this invention. Furthermore, the food / beverage products of this invention can be taken on a daily basis, and as a result, an antiallergic and whitening effect can be realized on a daily basis.
以下、本発明を説明する。
本発明の抗アレルギー性組成物は、豆類及びルイボス茶のうちの少なくとも１つを含む培地に乳酸菌を接種し、発酵培養して得られた乳酸菌発酵組成物を含有することを特徴とする。
また、本発明の美白組成物は、ルイボス茶及びバラのうちの少なくとも一方を含む培地にラクトバチルス属に属する乳酸菌を接種し、発酵培養して得られた乳酸菌発酵組成物を含有することを特徴とする。更に、他の本発明の美白組成物は、大豆を含む培地にロイコノストック属に属する乳酸菌又はLactobacillus casei subsp.caseiを接種し、発酵培養して得られた乳酸菌発酵組成物を含有することを特徴とする。
The present invention will be described below.
The antiallergic composition of the present invention is characterized by containing a lactic acid bacterium fermentation composition obtained by inoculating a lactic acid bacterium in a medium containing at least one of beans and rooibos tea and fermenting it.
Further, the whitening composition of the present invention contains a lactic acid bacteria fermentation composition obtained by inoculating a culture medium containing at least one of rooibos tea and rose with a lactic acid bacterium belonging to the genus Lactobacillus and fermenting it. And Furthermore, another whitening composition of the present invention contains a lactic acid bacteria fermentation composition obtained by inoculating a medium containing soybeans with lactic acid bacteria belonging to the genus Leuconostoc or Lactobacillus casei subsp. Features.
上記「豆類」は、一般に食用や飼料とされるマメ科の植物の種実であればその種類については特に限定はなく、例えば、大豆、黒大豆、落花生、小豆、ササゲ、インゲンマメ、ソラマメ、エンドウ豆、緑豆、コーヒー豆、カカオ豆、ゴマ種子、ヒマワリ種子等が挙げられる。その他に脱脂豆、脱脂種実、キナ粉、豆粉、豆カス及びこれらの加水分解物等を用いることもできる。また、上記「豆類」の形態には特に限定はなく、通常の形態の他、粉砕等した粉末品でもよい。 The above-mentioned “beans” are not particularly limited as long as they are seeds of leguminous plants that are generally used for food and feed. For example, soybeans, black soybeans, peanuts, red beans, cowpeas, kidney beans, broad beans, peas , Green beans, coffee beans, cacao beans, sesame seeds, sunflower seeds and the like. In addition, defatted beans, defatted seeds, quina flour, bean flour, bean residue and hydrolysates thereof can also be used. In addition, the form of the “beans” is not particularly limited, and may be a powder product obtained by pulverization in addition to a normal form.
上記「ルイボス茶」は、アスパラサス・リネアリス（Aspalathus linealis ）又はアスパラサス・セダルベルゲンシス（Aspalathus cedarbergensis ）の葉を酵素発酵させて得られる発酵茶である。上記「ルイボス茶」は、茶葉の状態で使用してもよく、その他、必要に応じて更に裁断等したり、あるいは粉砕等した粉末品でもよい。 The “Rooibos tea” is a fermented tea obtained by enzymatic fermentation of the leaves of Aspalathus linealis or Aspalathus cedarbergensis. The “Rooibos tea” may be used in the form of tea leaves, or may be a powder product that is further cut or pulverized as necessary.
上記「バラ」としては、バラ科バラ属に属するバラ（Ｒｏｓａ ｓｐｐ．）が好ましく、具体的には、ロサ・ガリカ（Ｒｏｓａ ｇａｌｌｉｃａ）、ロサ・モスカタ（Ｒｏｓａ ｍｏｓｃｈａｔａ）、ロサ・フォエティダ（Ｒｏｓａ ｆｏｅｔｉｄａ）、ロサ・ギガンテア（Ｒｏｓａ ｇｉｇａｎｔｅａ）、ノイバラ（Ｒｏｓａ ｍｕｌｔｉｆｌｏｒａ）、テリハノイバラ（Ｒｏｓａ ｗｉｃｈｕｒａｉａｎａ）等の野生種、又はこれらを交配して得られた園芸種が挙げられる。また、本発明の美白組成物において、上記「バラ」の使用部位について特に限定はなく、花、花びら、葉、茎、根及び種子等のどの部分を使用してもよい。 As the “rose”, rose belonging to the genus Rosaceae (Rosa spp.) Is preferable, and specifically, Rosa gallica, Rosa moschata, Rosa foetida. And wild species such as Rosa gigantea, Rosa multiflora and Teri Hanoi rose, or horticultural species obtained by crossing them. In the whitening composition of the present invention, there is no particular limitation on the use site of the “rose”, and any part such as flowers, petals, leaves, stems, roots and seeds may be used.
本発明において、上記「豆類」、「ルイボス茶」、及び「バラ」としては、上記豆類、ルイボス茶、及びバラを原料として抽出することにより得られる抽出物でもよい。ここで、上記「抽出物」としては、抽出液を濾過したままの液でもよいし、これを濃縮した濃縮液でもよい。その他にも、凍結乾燥等の公知の方法により、上記抽出液や濃縮液から溶媒を除去した固形物や粉末化した粉末物でもよく、これらの固形物や粉末物を溶媒に溶解又は分散させた溶液又は分散液でもよい。更に、上記「抽出物」としては、抽出することにより得られる抽出物を、タンナーゼ等の酵素を用いて酵素処理したものでもよい。更に、上記「豆類」の抽出物には、豆類煮汁、特に豆類の加工における通常の加工工程で生じる豆類煮汁廃液や豆腐凝固工程等で副生する浸出液若しくはその濃縮液又はそれらの固形物や粉末物を用いてもよい。これらを用いると、従来は廃棄処分されていた豆類煮汁廃液や浸出液の有効利用を図ることもできるので好ましい。また、上記「抽出物」は、そのままの状態で用いてもよいが、抽出効率向上や品質維持等のために、法的に許されている添加物を使用することもできる。 In the present invention, the “beans”, “rooibos tea”, and “rose” may be extracts obtained by extracting the beans, rooibos tea, and rose as raw materials. Here, the “extract” may be a liquid obtained by filtering the extract or a concentrated liquid obtained by concentrating the extract. In addition, it may be a solid or powdered powder obtained by removing the solvent from the extract or the concentrated liquid by a known method such as freeze-drying, and the solid or powder is dissolved or dispersed in the solvent. It may be a solution or a dispersion. Furthermore, as the “extract”, an extract obtained by extraction may be subjected to an enzyme treatment using an enzyme such as tannase. Furthermore, the extract of the above-mentioned “beans” includes legume boiled juice, in particular, a legume boiled waste liquid produced in a normal processing step in legume processing, a leachate produced as a by-product in a tofu coagulation step or the like, a concentrated liquid thereof, or a solid or powder thereof. You may use thing. Use of these is preferable because it is possible to effectively use the bean broth waste liquid and the leachate that have been disposed of in the past. The above-mentioned “extract” may be used as it is, but legally permitted additives may be used for improving extraction efficiency and maintaining quality.
上記「抽出物」を得るための抽出方法、抽出条件については特に限定はない。例えば、抽出原料は未粉砕でも、粉砕したものでもよく、抽出物の品質を維持できる限り、不純物除去等の前処理をしてもよい。また、抽出溶媒としては、水又は熱水の他、エタノール、酢酸エチル、ｎ−ヘキサン等の有機溶媒や、これらの有機溶媒と水又は熱水との混合溶媒等を用いることができ、このうち、特に熱水が好ましい。熱水の温度は、通常、４０〜１００℃、好ましくは５０〜８０℃、更に好ましくは５０〜７０℃である。また、抽出の際の抽出溶媒のｐＨは通常３〜７、好ましくは４〜６、更に好ましくは４〜５である。ｐＨを上記範囲内とすることにより、抽出原料に含まれている各種成分の安定性を保つことができるので好ましい。抽出温度は特に制限されないが、常温又は加熱抽出が好ましい。加熱抽出の場合、加熱温度としては通常４０〜１００℃、好ましくは５０〜８０℃、更に好ましくは５０〜７０℃である。加熱温度をかかる範囲とすることにより、抽出を効率的に行うことができるので好ましい。 The extraction method and extraction conditions for obtaining the “extract” are not particularly limited. For example, the extraction raw material may be unground or pulverized, and may be subjected to pretreatment such as impurity removal as long as the quality of the extract can be maintained. As the extraction solvent, water or hot water, organic solvents such as ethanol, ethyl acetate and n-hexane, mixed solvents of these organic solvents and water or hot water, and the like can be used. In particular, hot water is preferred. The temperature of the hot water is usually 40 to 100 ° C, preferably 50 to 80 ° C, more preferably 50 to 70 ° C. In addition, the pH of the extraction solvent during extraction is usually 3 to 7, preferably 4 to 6, and more preferably 4 to 5. By setting the pH within the above range, it is preferable because the stability of various components contained in the extraction raw material can be maintained. The extraction temperature is not particularly limited, but normal temperature or heat extraction is preferable. In the case of heat extraction, the heating temperature is usually 40 to 100 ° C, preferably 50 to 80 ° C, more preferably 50 to 70 ° C. By setting the heating temperature to such a range, extraction can be efficiently performed, which is preferable.
上記「乳酸菌」は、糖類を発酵して乳酸を生成する性質を有する細菌の総称であり、グラム陽性の桿菌又は球菌であり、内性胞子を形成せず、カタラーゼ陰性であり、消費したブドウ糖に対し、５０％以上の乳酸を産生する乳酸菌が好ましい。上記「乳酸菌」の代表的なものとして例えば、ラクトバチルス属、ストレプトコッカス属、ラクトコッカス属、ペディオコッカス属、及びロイコノストック属等が含まれる。また、本発明の上記「乳酸菌」には、ビフィズス菌属（ビフィドバクテリウム属）も含まれる。本発明の抗アレルギー性組成物及び本発明の美白組成物において、上記「乳酸菌」は、市販されている一般的なものを用いるのが通常であるが、自然的、又はニトロソグアニジン等の化学物質、Ｘ線、紫外線等により人為的変異手段により得られ、菌学的性質が変異した変異株であっても、抗アレルギー作用及び美白作用を有する乳酸菌発酵組成物を産出する性質を失わない限り利用することができる。 The above-mentioned “lactic acid bacteria” is a general term for bacteria having the property of fermenting sugars to produce lactic acid. Gram-positive bacilli or cocci that do not form endogenous spores, are catalase-negative, On the other hand, lactic acid bacteria that produce 50% or more of lactic acid are preferred. Representative examples of the “lactic acid bacterium” include the genus Lactobacillus, Streptococcus, Lactococcus, Pediococcus, and Leuconostoc. Further, the above-mentioned “lactic acid bacterium” of the present invention includes a genus Bifidobacterium (genus Bifidobacterium). In the antiallergic composition of the present invention and the whitening composition of the present invention, the above-mentioned “lactic acid bacterium” is usually a commercially available general one, but natural or a chemical substance such as nitrosoguanidine. Even if it is a mutant strain obtained by artificial mutation means with X-rays, ultraviolet rays, etc. and having mycological properties mutated, it should be used as long as it does not lose the property of producing a lactic acid bacteria fermentation composition having antiallergic and whitening effects. can do.
上記ラクトバチルス属に属する菌種としては、例えば、Lactobacillus acidophilus、Lactobacillus brevis、Lactobacillus bulgaricus、Lactobacillus casei、Lactobacillus cellobiosus、Lactobacillus delbruckii、Lactobacillus fermenti、Lactobacillus helveticus、Lactobacillus jugurti、Lactobacillus kefiri、Lactobacillus lactis、Lactobacillus plantarum、Lactobacillus vaccinostercus、Sporolactobacillus inulinus等が挙げられる。
上記ストレプトコッカス属に属する菌種としては、例えば、Streptococcus cremoris、Streptococcus diacetilactis、Streptococcus faecalis、Streptococcus faecium、Streptococcus lactis、Streptococcus lactis sub-sp. diacetylactis、Streptococcusthermophilus、Streptococcus uberis等が挙げられる。
上記ラクトコッカス属に属する菌種としては、例えば、Lactococcus lactis subsp.cremoris、Lactococcus lactis subsp.lactis、Lactococcus lactis subsp.hordniae等が挙げられる。
上記ペディオコッカス属に属する菌種としては、例えば、Pediococcus acidilactis、Pediococcus cerevisiae、Pediococcus halophilus、Pediococcus pentosaceus等が挙げられる。 上記ロイコノストック属に属する菌種としては、例えば、Leuconostoc citrovorum、Leuconostoc cremoris、Leuconostoc dextranicum、Leuconostoc mesenteroides等が挙げられる。この中で、特にLeuconostoc mesenteroidesが好ましく用いられる。
上記ビフィズス菌属に属する菌種としては、例えば、Bifidobacterium adolescentis、Bifidobacterium bifidum、Bifidobacterium breve、Bifidobacterium infantis、Bifidobacterium lactentis、Bifidobacterium liberorum、Bifidobacterium longum、Bifidobacterium parvulorum、Bifidobacterium pseudolongum、Bifidobacterium thermophilum等が挙げられる。
Examples of the bacterial species belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus cellobiosus, Lactobacillus delbruckii, Lactobacillus fermenti, Lactobacillus helveticoba, Lactobacillus helveticoba, Lactobacillus Examples include vaccinostercus and Sporolactobacillus inulinus.
Examples of the species belonging to the genus Streptococcus include Streptococcus cremoris, Streptococcus diacetilactis, Streptococcus faecalis, Streptococcus faecium, Streptococcus lactis, Streptococcus lactis sub-sp. Diacetylactis, Streptococcusthermophilus, and Streptococcus ube.
Examples of the bacterial species belonging to the genus Lactococcus include Lactococcus lactis subsp.cremoris, Lactococcus lactis subsp.lactis, Lactococcus lactis subsp.hordniae, and the like.
Examples of the bacterial species belonging to the genus Pediococcus include Pediococcus acidilactis, Pediococcus cerevisiae, Pediococcus halophilus, Pediococcus pentosaceus and the like. Examples of the bacterial species belonging to the genus Leuconostoc include Leuconostoc citrovorum, Leuconostoc cremoris, Leuconostoc dextranicum, Leuconostoc mesenteroides, and the like. Among these, Leuconostoc mesenteroides is particularly preferably used.
Examples of the species belonging to the genus Bifidobacterium include Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactentis, Bifidobacterium liberorum, Bifidobacterium longum, Bifidobacterium parvulorum, Bifidobacterium pseudolongum, and Bifidobacterium thermophilum.
本発明の抗アレルギー性組成物では、上記乳酸菌の種類は、必要に応じて種々選択することができる。上記乳酸菌として、ラクトバチルス属、ラクトコッカス属、及びロイコノストック属に属する乳酸菌から選ばれる少なくとも１種を用いると、より抗アレルギー性に優れた抗アレルギー性組成物が得られるので好ましく、特にLactobacillus brevis、Lactobacillus casei subsp.casei、Lactococcus lactis subsp.hordniae、及びLeuconostoc mesenteroides subsp.mesenteroidesから選ばれる少なくとも１種を用いると、更に抗アレルギー性に優れた抗アレルギー性組成物が得られるので好ましい。尚、本発明の抗アレルギー性組成物において、上記乳酸菌は１種単独でもよく、２種以上用いてもよい。 In the antiallergic composition of the present invention, the type of the lactic acid bacteria can be variously selected as necessary. As the lactic acid bacterium, it is preferable to use at least one selected from lactic acid bacteria belonging to the genus Lactobacillus, Lactococcus, and Leuconostoc, since an antiallergic composition having more excellent antiallergic properties can be obtained, and in particular, Lactobacillus Use of at least one selected from brevis, Lactobacillus casei subsp. casei, Lactococcus lactis subsp. hordniae, and Leuconostoc mesenteroides subsp. mesenteroides is preferable because an antiallergic composition having further excellent antiallergic properties can be obtained. In the antiallergic composition of the present invention, the lactic acid bacteria may be used alone or in combination of two or more.
一方、本発明の美白組成物では、原料としてルイボス茶及びバラのうちの少なくとも一方を用いた場合、乳酸菌として、上記乳酸菌の中からラクトバチルス属に属する乳酸菌を用い、原料として大豆を用いた場合は、ロイコノストック属に属する乳酸菌又はラクトバチルス属に属する乳酸菌であるLactobacillus casei subsp.caseiを用いる。これらの乳酸菌を用いると、チロシナーゼ阻害作用を増強することができ、その結果、美白作用に優れた美白組成物を得ることができる。また、原料としてルイボス茶及びバラのうちの少なくとも一方を用いた場合、乳酸菌として、Lactobacillus brevis及び／又はLactobacillus casei subsp.caseiを用いると、更にチロシナーゼ阻害作用を増強させ、美白作用を向上させることができるので好ましい。尚、本発明の美白組成物において、上記乳酸菌は１種単独でもよく、２種以上用いてもよい。 On the other hand, in the whitening composition of the present invention, when at least one of rooibos tea and rose is used as a raw material, as a lactic acid bacterium, a lactic acid bacterium belonging to the genus Lactobacillus is used among the above lactic acid bacteria, and a soybean is used as a raw material Uses Lactobacillus casei subsp.casei, which is a lactic acid bacterium belonging to the genus Leuconostoc or a lactic acid bacterium belonging to the genus Lactobacillus. When these lactic acid bacteria are used, the tyrosinase inhibitory action can be enhanced, and as a result, a whitening composition having an excellent whitening action can be obtained. In addition, when at least one of rooibos tea and rose is used as a raw material, when Lactobacillus brevis and / or Lactobacillus casei subsp.casei is used as a lactic acid bacterium, the tyrosinase inhibitory action can be further enhanced and the whitening action can be improved. It is preferable because it is possible. In the whitening composition of the present invention, the lactic acid bacteria may be used alone or in combination of two or more.
上記乳酸菌発酵組成物を得るための発酵条件は、抗アレルギー作用及び美白作用を奏する乳酸菌発酵組成物が得られる限り特に限定はない。発酵培養は通常、通気攪拌を行うことにより行われる。また、培養を行うための培地についても、上記乳酸菌が増殖できるものであれば特に制限はなく、通常は液体培地であるが、固形培地でもかまわない。また、培地のｐＨは通常４〜７、好ましくは５〜７、更に好ましくは６〜７である。このｐＨを上記の範囲内とすると、抽出原料に含まれている各種成分の安定性を保つことができるので好ましい。更に、培養温度についても、発酵が行われる限り特に制限はなく、通常４０〜４５℃程度である。また、培養の際、糖等の各種の栄養素やｐＨ調製のための酸、アルカリ等を適宜加えてもよい。更に、発酵は、混合発酵でも連続発酵でもよい。 Fermentation conditions for obtaining the lactic acid bacteria fermentation composition are not particularly limited as long as a lactic acid bacteria fermentation composition exhibiting an antiallergic action and a whitening action is obtained. Fermentation culture is usually performed by aeration and agitation. Further, the medium for culturing is not particularly limited as long as the lactic acid bacteria can grow, and is usually a liquid medium, but may be a solid medium. Moreover, the pH of a culture medium is 4-7 normally, Preferably it is 5-7, More preferably, it is 6-7. If this pH is within the above range, it is preferable because the stability of various components contained in the extraction raw material can be maintained. Furthermore, there is no restriction | limiting in particular also about culture | cultivation temperature as long as fermentation is performed, and it is about 40-45 degreeC normally. Further, during the cultivation, various nutrients such as sugar, acid for adjusting pH, alkali, etc. may be added as appropriate. Furthermore, the fermentation may be mixed fermentation or continuous fermentation.
本発明の抗アレルギー性組成物及び本発明の美白組成物の形態については特に限定はなく、それぞれ培養して得られた培養発酵液を濾過したままの液でもよいし、これを滅菌処理やｐＨ調整をしたり、あるいは、イオン交換樹脂、活性炭カラム、又は透析膜等を利用し、脱臭・脱色等の後処理をした液でもよい。更には、これを濃縮した濃縮液やペースト状物でもよい。その他にも、凍結乾燥等の公知の方法により溶媒を除去した固形物や粉末化した粉末物でもよい。更には、必要に応じて、水若しくはエタノール、プロピレングリコール及び１，３−ブチレングリコール等の有機溶媒、又はこれらの混合溶媒に添加して溶解又は分散液としてもよい。 There is no particular limitation on the form of the antiallergic composition of the present invention and the whitening composition of the present invention, and the culture fermentation liquid obtained by culturing each may be a filtered liquid, which may be sterilized or pH-treated. It may be a liquid that has been subjected to post-treatment such as deodorization and decolorization using an ion exchange resin, an activated carbon column, or a dialysis membrane. Further, a concentrated solution or a paste-like product obtained by concentrating the same may be used. In addition, a solid or powdered powder from which the solvent has been removed by a known method such as freeze-drying may be used. Furthermore, if necessary, it may be added to water or an organic solvent such as ethanol, propylene glycol and 1,3-butylene glycol, or a mixed solvent thereof to form a solution or dispersion.
本発明の抗アレルギー性組成物及び本発明の美白組成物は、抗アレルギー性及び美白作用という効果を奏すると共に、天然素材を使用しているので、従来の合成アレルギー剤等の合成物質と比較して安全性も高い。よって、本発明の飲食品のように、飲料や食品に添加することにより、日常的に摂取することができる。また、本発明の美白組成物は、化粧品素材として使用することにより、本発明の化粧品のような美白化粧品を得ることができる。本発明の抗アレルギー性組成物及び本発明の美白組成物に含まれる乳酸菌発酵組成物の量（固形分換算、Ｗ／Ｖ）は、通常０．０００１％以上、好ましくは０．０００５〜１％更に好ましくは、０．００１〜０．５％、最も好ましくは０．０１〜０．０５％である。本発明の抗アレルギー性組成物及び本発明の美白組成物に含まれるバラ発酵組成物の量が０．０００１％未満では、抗アレルギー作用及び美白作用が減弱するので好ましくない。また、１％を超える量を添加しても、抗アレルギー作用及び美白作用は頭打ちとなるので、経済的に好ましくない。 The antiallergic composition of the present invention and the whitening composition of the present invention have the effects of antiallergenicity and whitening action and use natural materials, so compared with synthetic substances such as conventional synthetic allergic agents. And high safety. Therefore, it can be ingested on a daily basis by adding it to beverages and foods like the food and drink of the present invention. Moreover, the whitening composition of this invention can obtain whitening cosmetics like the cosmetics of this invention by using it as a cosmetic raw material. The amount of lactic acid bacteria fermentation composition contained in the antiallergic composition of the present invention and the whitening composition of the present invention (in terms of solid content, W / V) is usually 0.0001% or more, preferably 0.0005 to 1%. More preferably, it is 0.001 to 0.5%, and most preferably 0.01 to 0.05%. If the amount of the rose fermentation composition contained in the antiallergic composition of the present invention and the whitening composition of the present invention is less than 0.0001%, the antiallergic action and the whitening action are reduced. Further, even if an amount exceeding 1% is added, the antiallergic action and the whitening action reach a peak, which is economically undesirable.
以下、実施例により本発明を具体的に説明する。
（１）乳酸菌発酵組成物の調製
発酵に使用する乳酸菌として、以下の乳酸菌を使用した。そして、下記乳酸菌を１０ｍｌのＭＲＳ培地に一白金耳植菌し、３０℃で１日間培養することにより、乳酸菌種培養液を調製した。
乳酸菌Ａ；Lactobacillus brevis
乳酸菌Ｂ；Lactobacillus casei subsp.casei
乳酸菌Ｃ；Lactococcus lactis subsp.hordniae
乳酸菌Ｄ；Leuconostoc mesenteroides subsp.mesenteroides
Hereinafter, the present invention will be described specifically by way of examples.
(1) Preparation of lactic acid bacteria fermentation composition The following lactic acid bacteria were used as lactic acid bacteria used for fermentation. Then, a lactic acid bacteria seed culture solution was prepared by inoculating one platinum ear of the following lactic acid bacteria in 10 ml of MRS medium and culturing at 30 ° C. for 1 day.
Lactic acid bacteria A; Lactobacillus brevis
Lactic acid bacteria B; Lactobacillus casei subsp.
Lactic acid bacteria C; Lactococcus lactis subsp.
Lactic acid bacteria D; Leuconostoc mesenteroides subsp. Mesenteroides
乾燥バラ（ロサ・ガリカ）の花びら（粉砕品）１ｇに水道水１００ｍｌを加え、これを１２１℃で１５分間オートクレーブした後、遠心分離（１００００ｒｐｍ、１０分間）し、上清液（バラ抽出物）を得た。該バラ抽出物１０ｍｌに、上記乳酸菌種培養液を１ｍｌ植菌した。そして、３日間、３０℃で静置培養した後、遠心分離（１００００ｒｐｍ、１０分間）し、上清液を得た。この上清液をバラ発酵組成物とした。
また、抽出原料として、赤しそ粉末、てん茶粉末、とちゅう茶粉末、グァバ茶粉末、ルイボス茶粉末、大豆濃縮パウダー、及び小豆濃縮パウダーを用い、該抽出原料の各１ｇに蒸留水１００ｍｌを加え、これを１２１℃で１５分間オートクレーブした後、遠心分離（１００００ｒｐｍ、１０分間）し、上清液を得た。この上清液に、上記乳酸菌種培養液Ａ〜Ｄを１０％接種した。そして、３日間、３０℃で静置培養した後、遠心分離（１００００ｒｐｍ、１０分間）し、上清液を得た。この上清液を上記各抽出原料の乳酸菌発酵組成物とした。
Add 100 ml of tap water to 1 g of dried rose (Rosa Galica) petals (crushed product), autoclav it at 121 ° C. for 15 minutes, then centrifuge (10000 rpm, 10 minutes) and supernatant (rose extract) Got. 1 ml of the lactic acid bacteria seed culture was inoculated into 10 ml of the rose extract. And after stationary culture at 30 degreeC for 3 days, it centrifuged (10000 rpm, 10 minutes), and obtained the supernatant liquid. This supernatant was used as a rose fermentation composition.
In addition, red perilla powder, tencha powder, tochu tea powder, guava tea powder, rooibos tea powder, soybean concentrated powder, and red bean concentrated powder were used as extraction raw materials, and 100 ml of distilled water was added to each 1 g of the extraction raw materials. This was autoclaved at 121 ° C. for 15 minutes and then centrifuged (10000 rpm, 10 minutes) to obtain a supernatant. This supernatant was inoculated with 10% of the above lactic acid bacteria seed cultures A to D. And after stationary culture at 30 degreeC for 3 days, it centrifuged (10000 rpm, 10 minutes), and obtained the supernatant liquid. This supernatant was used as the lactic acid bacteria fermentation composition of each of the above extraction raw materials.
（２）評価
上記方法により得られた各乳酸菌発酵組成物及び乳酸菌発酵前の上清液（抽出液）をサンプルとし、以下の方法により、ＩｇＥ−ＩｇＥレセプター結合阻害活性及びチロシナーゼ阻害活性を測定した。
〔１〕試験１（ＩｇＥ−ＩｇＥレセプター結合阻害活性）
９６穴マイクロプレートの各ウェルに９０ｎｇ／１００μｌのＩｇＥレセプター（遺伝子組替細胞により発現されたヒト高親和性ＩｇＥレセプターの構成成分の１つであるα鎖タンパク質）を入れ、４℃で一晩静置した。そして、上記ＩｇＥレセプターを回収した後、洗浄用緩衝液（ＰＢＳ〔ＮａＣｌ；８０ｇ／Ｌ、Ｎａ２ＨＰＯ４；１１ｇ／Ｌ、ＫＣＬ；２ｇ／Ｌ、ＫＨ２ＰＯ４４；２ｇ／Ｌ〕；１Ｌ、Ｔｗｅｅｎ２０；０．５ｍｌ）を各ウェルに１００μｌ加え、５回洗浄した。次いで、特異的な吸着を避けるために、ブロック用緩衝液（ＰＢＳ；１Ｌ、カゼイン；１ｇ、ＮａＮ３；０．０２ｇ）を各ウェルに１５０μｌ入れ、３７℃で１時間インキュベートした。その後、最終濃度が０．０２〜２０％になるように調製したサンプルと、希釈用緩衝液（ＰＢＳ；１００ｍｌ、カゼイン；０．１ｇ）を用いて最終濃度が４００ｎｇ／ｍｌになるように調製したヒトＩｇＥ抗体を、各ウェル当たり１００μｌになるように加え、３７℃で３時間インキュベートした。インキュベート終了後、上記洗浄用緩衝液を各ウェルに１００μｌ加えて５回洗浄することにより、遊離のサンプル及びヒトＩｇＥ抗体を除去した。
(2) Evaluation Each lactic acid bacteria fermentation composition obtained by the above method and the supernatant (extract) before lactic acid bacteria fermentation were used as samples, and IgE-IgE receptor binding inhibitory activity and tyrosinase inhibitory activity were measured by the following methods. .
[1] Test 1 (IgE-IgE receptor binding inhibitory activity)
90 ng / 100 μl of IgE receptor (alpha chain protein which is one of the components of human high affinity IgE receptor expressed by recombinant cells) is placed in each well of a 96-well microplate and allowed to stand overnight at 4 ° C. I put it. After recovering the IgE receptor, a washing buffer (PBS [NaCl; 80 g / L, Na 2 HPO 4 ; 11 g / L, KCL; 2 g / L, KH 2 PO4 4 ; 2 g / L]; 1 L, 100 μl of Tween 20 (0.5 ml) was added to each well and washed 5 times. Next, in order to avoid specific adsorption, 150 μl of blocking buffer (PBS; 1 L, casein; 1 g, NaN 3 ; 0.02 g) was placed in each well and incubated at 37 ° C. for 1 hour. Thereafter, the final concentration was adjusted to 400 ng / ml using a sample prepared to a final concentration of 0.02 to 20% and a dilution buffer (PBS; 100 ml, casein; 0.1 g). Human IgE antibody was added to 100 μl per well and incubated at 37 ° C. for 3 hours. After the incubation was completed, 100 μl of the washing buffer was added to each well and washed 5 times to remove free samples and human IgE antibodies.
次に、西洋ワサビパーオキシダーゼ（ＨＲＰ）により標識した抗ヒトＩｇＥポリクローナル抗体を各ウェルに１００μｌ加え、３７℃で１時間インキュベートした後、上記洗浄用緩衝液を各ウェルに１００μｌ加えて５回洗浄することにより、遊離の抗ヒトＩｇＥ抗体を除去した。その後、ＨＲＰの基質としてＯ−フェニレンジアミン二塩酸塩（ＯＰＤ）を各ウェルに７５μｌ加えて遮光して１０〜３０分インキュベートして反応させ、発色させた後、各ウェルの４９０ｎｍにおける吸光度をマイクロプレートリーダーにて測定した。また、ヒトＩｇＥ及び試料を添加しなかった場合の吸光度を（Ａ）、ヒトＩｇＥのみを添加して試料を加えなかった場合の吸光度を（Ｂ）、試料のみを添加してヒトＩｇＥを加えなかった場合の吸光度を（Ｃ）、更にヒトＩｇＥ及び試料を添加した場合の吸光度を（Ｄ）として測定し、以下の式によりヒトＩｇＥ−ＩｇＥレセプター結合阻害率（％）を求めた。その結果を表１に示す。
阻害率（％）＝［１−（Ｄ−Ｃ）／（Ｂ−Ａ）］×１００
Next, 100 μl of anti-human IgE polyclonal antibody labeled with horseradish peroxidase (HRP) is added to each well, incubated at 37 ° C. for 1 hour, and then washed by adding 100 μl of the above washing buffer to each well 5 times. This removed the free anti-human IgE antibody. Thereafter, 75 μl of O-phenylenediamine dihydrochloride (OPD) as a substrate for HRP was added to each well, and the mixture was allowed to react by incubation for 10 to 30 minutes in the dark. After color development, the absorbance at 490 nm of each well was measured using a microplate. Measured with a reader. In addition, the absorbance when human IgE and the sample are not added is (A), the absorbance when only human IgE is added and the sample is not added is (B), and only the sample is added and human IgE is not added (C), the absorbance when human IgE and a sample were further added were measured as (D), and the human IgE-IgE receptor binding inhibition rate (%) was determined by the following formula. The results are shown in Table 1.
Inhibition rate (%) = [1- (DC) / (BA)] × 100
〔２〕試験２（チロシナーゼ阻害活性）
メラニン色素は、チロシナーゼの作用によってチロシンから生成される。このため、チロシナーゼ阻害作用が高いものは、美白作用に優れていると言える。そこで、以下の方法により、チロシナーゼ阻害活性を測定した。
ワッセルマン試験管に１．６６ｍＭチロシンを溶解したＭｃｉｌｖａｉｎｅ緩衝液（ｐＨ６．８）を１ｍｌずつ分注した。そして、これに上記サンプルを各４５０μｌずつ加えて３７℃で３分間プレインキュベートした。
次いで、１２００単位／ｍｌのチロシナーゼを１００μｌずつ加え、３７℃で１０分間インキュベートした後、１．０Ｍアジ化ナトリウムを５０μｌ加え、分光光度計で４７５ｎｍの吸光度を測定した。ブランクの場合は、チロシナーゼ添加前に１．０Ｍアジ化ナトリウムを５０μｌ加えて吸光度（Ｔ０）を測定した。また、コントロールとして蒸留水４５０μｌを用いて同様に実験を行って吸光度（Ｃ）を測定した。また、そして、以下の式により、チロシナーゼ阻害活性（％）を求めた。その結果を表２に示す。
チロシナーゼ阻害活性（％）＝｛１−（Ｔ−Ｔ０）／（Ｃ−Ｃ０）｝×１００
Ｔ；サンプルの吸光度、 Ｔ０；サンプルのブランクの吸光度
Ｃ；コントロールの吸光度、Ｃ０；コントロールのブランクの吸光度
[2] Test 2 (tyrosinase inhibitory activity)
Melanin pigment is produced from tyrosine by the action of tyrosinase. For this reason, it can be said that the thing with a high tyrosinase inhibitory effect is excellent in the whitening effect | action. Therefore, tyrosinase inhibitory activity was measured by the following method.
1 ml each of Mcilvine buffer solution (pH 6.8) in which 1.66 mM tyrosine was dissolved was dispensed into a Wasselman test tube. And 450 microliters of said samples were each added to this, and it pre-incubated for 3 minutes at 37 degreeC.
Next, 100 μl of 1200 units / ml tyrosinase was added and incubated at 37 ° C. for 10 minutes, 50 μl of 1.0 M sodium azide was added, and the absorbance at 475 nm was measured with a spectrophotometer. In the case of a blank, 50 μl of 1.0 M sodium azide was added before adding tyrosinase, and the absorbance (T 0 ) was measured. Further, the absorbance (C) was measured in the same manner using 450 μl of distilled water as a control. And tyrosinase inhibitory activity (%) was calculated | required by the following formula | equation. The results are shown in Table 2.
Tyrosinase inhibitory activity (%) = {1− (T−T 0 ) / (C−C 0 )} × 100
T: Absorbance of sample, T 0 ; Absorbance of sample blank C: Absorbance of control, C 0 ; Absorbance of control blank
（６）実施例の結果
表１より、大豆濃縮パウダー、小豆濃縮パウダー、及びルイボス茶では、発酵前の抽出物のＩｇＥ−ＩｇＥレセプター結合阻害活性が１４〜６７％なのに対し、乳酸菌発酵組成物のＩｇＥ−ＩｇＥレセプター結合阻害活性は７０〜１００％であり、乳酸菌発酵前の抽出物と比べて高いことが分かる。
一方、赤しそ、てん茶、とちゅう茶、及びグァバ茶は、発酵前の抽出物のＩｇＥ−ＩｇＥレセプター結合阻害活性が２９〜８７％なのに対し、乳酸菌発酵組成物のＩｇＥ−ＩｇＥレセプター結合阻害活性は０％であり、乳酸菌発酵により、却って抗アレルギー性が著しく低下していることが分かる。
これらの結果から、本発明の抗アレルギー性組成物のように、特定の原料の乳酸菌組成物とすることにより、抗アレルギー性を増強することができることが分かる。
(6) Results of Examples From Table 1, in the soybean concentrated powder, red bean concentrated powder, and rooibos tea, the extract before fermentation had an IgE-IgE receptor binding inhibitory activity of 14 to 67%, whereas the lactic acid bacteria fermentation composition had It can be seen that the IgE-IgE receptor binding inhibitory activity is 70 to 100%, which is higher than the extract before lactic acid bacteria fermentation.
On the other hand, red shiso, tencha, tochu tea, and guava tea have an IgE-IgE receptor binding inhibitory activity of the extract before fermentation of 29 to 87%, whereas the lactic acid bacteria fermentation composition has an IgE-IgE receptor binding inhibitory activity. Is 0%, and it can be seen that anti-allergic properties are significantly reduced by lactic acid bacteria fermentation.
From these results, it can be seen that anti-allergic properties can be enhanced by using a lactic acid bacteria composition of a specific raw material as in the anti-allergic composition of the present invention.
表２より、ルイボス茶及びバラの場合、発酵前の抽出物と、ラクトバチルス属に属する乳酸菌である乳酸菌Ａ及びＢによる乳酸菌発酵組成物とを対比すると、発酵前の抽出物と比べて、乳酸菌発酵組成物の方がチロシナーゼ阻害作用が大きいことが分かる。これに対し、ラクトコッカス属に属する乳酸菌である乳酸菌Ｃ及びロイコノストック属に属する乳酸菌である乳酸菌Ｄによる乳酸発酵抽出物は、発酵前の抽出物と比べて、チロシナーゼ阻害作用がほぼ同程度か、あるいは低下していることが分かる。
また、大豆濃縮パウダーの場合、発酵前の抽出物と、ロイコノストック属に属する乳酸菌である乳酸菌Ｂによる乳酸菌発酵組成物及び乳酸菌Ｄ（Leuconostoc mesenteroides subsp.mesenteroides）による乳酸菌発酵組成物とを対比すると、発酵前の抽出物と比べて、乳酸菌発酵組成物の方がチロシナーゼ阻害作用が大きいことが分かる。これに対し、他のラクトバチルス属に属する乳酸菌である乳酸菌Ａによる乳酸菌発酵組成物及びラクトコッカス属に属する乳酸菌である乳酸菌Ｃによる乳酸発酵抽出物は、発酵前の抽出物と比べて、チロシナーゼ阻害作用がほぼ同程度であり、チロシナーゼ阻害作用の増強が認められなかったことが分かる。
一方、小豆濃縮パウダー、赤しそ、てん茶、とちゅう茶、及びグァバ茶の場合、発酵前の抽出物と乳酸菌発酵組成物とのチロシナーゼ阻害作用を対比すると、ほぼ同程度が、あるいは却ってチロシナーゼ阻害作用が低下していることが分かる。
これらの結果から、本発明の美白組成物のように、特定の原料を用い、特定の乳酸菌により発酵した乳酸菌発酵組成物とすることにより、美白作用を増強することができることが分かる。
From Table 2, in the case of rooibos tea and rose, when the extract before fermentation and the lactic acid bacteria fermentation composition by lactic acid bacteria A and B, which are lactic acid bacteria belonging to the genus Lactobacillus, are compared with the extract before fermentation, lactic acid bacteria It can be seen that the fermented composition has a greater tyrosinase inhibitory effect. On the other hand, the lactic acid fermentation extract by lactic acid bacteria C belonging to the genus Lactococcus and lactic acid bacteria D belonging to the genus Leuconostoc has almost the same level of tyrosinase inhibitory action as the extract before fermentation. Or it can be seen that it is decreasing.
In the case of soybean concentrated powder, the extract before fermentation is compared with the lactic acid bacteria fermentation composition by lactic acid bacteria B, which is a lactic acid bacterium belonging to the genus Leuconostoc, and the lactic acid bacteria fermentation composition by lactic acid bacteria D (Leuconostoc mesenteroides subsp. Mesenteroides). It can be seen that the lactic acid bacteria fermentation composition has a larger tyrosinase inhibitory action than the extract before fermentation. On the other hand, the lactic acid bacteria fermentation composition by lactic acid bacteria A which is another lactic acid bacterium belonging to the genus Lactobacillus and the lactic acid fermentation extract by lactic acid bacteria C which is the lactic acid bacterium belonging to the genus Lactococcus are tyrosinase-inhibited compared with the extract before fermentation. It can be seen that the effects were almost the same, and no enhancement of the tyrosinase inhibitory effect was observed.
On the other hand, in the case of red bean concentrate powder, red shiso, tencha, tochu tea, and guava tea, when comparing the tyrosinase inhibitory action of the extract before fermentation and the lactic acid bacteria fermentation composition, it is almost the same, or on the contrary, tyrosinase inhibition It turns out that the effect | action has fallen.
From these results, it can be seen that the whitening action can be enhanced by using a specific raw material and fermenting with a specific lactic acid bacterium as in the whitening composition of the present invention.
尚、本発明では、上記具体的実施例に示すものに限られず、目的、用途に応じて本発明の範囲内で種々変更した実施例とすることができる。即ち、上記組成物の形態は、通常、水溶液若しくは原液等の液状であるが、これに限らず、この抽出物を吸液性粉末に含浸させた粉末品、造粒した造粒品、増量剤等他の粉末成分を配合した錠剤、又はマイクロカプセル等とすることができる。また、これらの水溶液、粉末品等を所定容器に充填してなる商品形態、またこれ単独で使用するか他剤（水溶液のもの、油性液のもの若しくは粉末を問わない。）に配合して使用するかについても特に限定されず、例えば、ポーション型でもよいし、他形状容器に充填してもよいし、粉末品をスティック状容器（袋）に充填したものでもよい。更に、従来の清涼飲料水、ドリンク剤、乳製品、油剤化製品等に配合、分散して使用してもよい。尚、この分散は油中水型、水中油型を問わない。また、他の栄養成分（例えば、各種ビタミン類、カルシウムイオン成分、鉄イオン成分等）、薬効成分、調味成分、匂い成分等を配合してもよい。これらのうち、特に水溶性成分が好ましい。均一に溶解した商品とすることができるからである。 The present invention is not limited to the specific examples described above, and can be variously modified examples within the scope of the present invention depending on the purpose and application. That is, the form of the above composition is usually a liquid such as an aqueous solution or a stock solution, but is not limited thereto, and a powder product obtained by impregnating the extract with a liquid absorbent powder, a granulated product obtained by granulation, and a bulking agent. It can be set as a tablet or a microcapsule etc. which mix | blended other powder components. In addition, a product form in which these aqueous solutions and powders are filled in a predetermined container, or these can be used alone or mixed with other agents (whether aqueous solutions, oily liquids or powders). There is no particular limitation on whether or not to perform, for example, it may be a portion type, may be filled in a container of another shape, or may be a powder product filled in a stick-like container (bag). Furthermore, you may mix | blend and disperse | distribute to the conventional soft drink, a drink agent, a dairy product, an oil-formation product, etc. In addition, this dispersion | distribution does not ask | require water-in-oil type and an oil-in-water type. Moreover, you may mix | blend other nutrient components (For example, various vitamins, a calcium ion component, an iron ion component, etc.), a medicinal component, a seasoning component, an odor component, etc. Of these, water-soluble components are particularly preferable. It is because it can be set as the product melt | dissolved uniformly.
本発明は、優れた抗アレルギー性及びチロシナーゼ阻害作用を有することから、抗アレルギー性組成物、美白組成物及び該美白組成物を含有する化粧品に適用することができる。例えば、本発明は、飲料、食品、化粧品、医薬品等の分野に好適に利用できる。 Since the present invention has an excellent antiallergic property and tyrosinase inhibitory effect, it can be applied to an antiallergic composition, a whitening composition, and a cosmetic containing the whitening composition. For example, the present invention can be suitably used in fields such as beverages, foods, cosmetics, and pharmaceuticals.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004056862A JP4637491B2 (en) | 2004-03-01 | 2004-03-01 | Antiallergic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004056862A JP4637491B2 (en) | 2004-03-01 | 2004-03-01 | Antiallergic composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010198184A Division JP5274525B2 (en) | 2010-09-03 | 2010-09-03 | Whitening composition and cosmetics containing these |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005247708A JP2005247708A (en) | 2005-09-15 |
| JP4637491B2 true JP4637491B2 (en) | 2011-02-23 |
Family
ID=35028552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004056862A Expired - Fee Related JP4637491B2 (en) | 2004-03-01 | 2004-03-01 | Antiallergic composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4637491B2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4800015B2 (en) * | 2005-11-22 | 2011-10-26 | 株式会社カロッツェリアジャパン | Microbial cultures for suppressing the onset of dermatitis and products using them |
| JP2007197333A (en) * | 2006-01-24 | 2007-08-09 | Ina Food Ind Co Ltd | Anti-allergic agent |
| JP4737190B2 (en) * | 2006-12-12 | 2011-07-27 | ユーハ味覚糖株式会社 | Lactic acid fermented food composition of cacao mass and method for producing the same |
| JP2008239522A (en) * | 2007-03-26 | 2008-10-09 | Kaneka Corp | Antiallergic agent |
| DK2053050T3 (en) * | 2007-10-23 | 2011-11-21 | Kneipp Werke Kneipp Mittel Zentrale Gmbh & Co Kg | Aspalathin-like dihydrochalcone and method of preparation |
| KR100973942B1 (en) * | 2008-02-27 | 2010-08-04 | 주식회사 코리아나화장품 | Cosmetic Composition for Whitening of the Skin Comprising the Extract of Fermented Phaselous radiatus Seed |
| KR101068815B1 (en) * | 2008-08-12 | 2011-10-04 | 두두원발효(주) | Cosmetic composition for improving skin wrinkle and skin whitening comprising a soybean compound fermented by kimchi lactic acid bacteria complex |
| EP2161026B1 (en) * | 2008-09-05 | 2012-12-26 | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & Co. KG | Combination of extracts from various plants to improve the symptoms of dementia |
| CN102596980A (en) * | 2009-08-26 | 2012-07-18 | Rna公司 | Lipoteichoic acid-derived glycolipids, and compositions comprising same |
| KR101540843B1 (en) * | 2013-05-08 | 2015-07-30 | 재단법인 인천테크노파크 | manufacturing method of complex kimchi lactic |
| CN110122581B (en) * | 2019-05-23 | 2022-08-12 | 光明乳业股份有限公司 | Method for preparing fermented soybean milk from leuconostoc mesenteroides, prepared fermented soybean milk and application |
| CN111544322A (en) * | 2020-06-04 | 2020-08-18 | 广群化妆品科学技术研究院(广州)有限公司 | Lactobacillus casei nucleocapsid cosmetic raw material and preparation method thereof |
| CN116211767B (en) * | 2023-03-15 | 2023-09-01 | 广州杨森药业有限公司 | Preparation method and application of jasmine flower/black tea fermentation filtrate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03291233A (en) * | 1990-04-09 | 1991-12-20 | Toshiaki Miyagawa | Drug for pollinosis |
| JPH092959A (en) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | Immuno-globulin e antibody production suppressant and antiallergic agent |
| JPH09294574A (en) * | 1996-05-01 | 1997-11-18 | Kouhadou:Kk | Antioxidant drink having sod-like action |
| JP2003026582A (en) * | 2001-03-21 | 2003-01-29 | Microbio Co Ltd | Composition used for inhibition of cancer, reduction of infectious disease and promotion of health |
| JP2003159020A (en) * | 2001-11-27 | 2003-06-03 | Kagome Labio Kk | Method for producing fermented product of bean whole flour |
-
2004
- 2004-03-01 JP JP2004056862A patent/JP4637491B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03291233A (en) * | 1990-04-09 | 1991-12-20 | Toshiaki Miyagawa | Drug for pollinosis |
| JPH092959A (en) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | Immuno-globulin e antibody production suppressant and antiallergic agent |
| JPH09294574A (en) * | 1996-05-01 | 1997-11-18 | Kouhadou:Kk | Antioxidant drink having sod-like action |
| JP2003026582A (en) * | 2001-03-21 | 2003-01-29 | Microbio Co Ltd | Composition used for inhibition of cancer, reduction of infectious disease and promotion of health |
| JP2003159020A (en) * | 2001-11-27 | 2003-06-03 | Kagome Labio Kk | Method for producing fermented product of bean whole flour |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005247708A (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2474237B1 (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| JP4637491B2 (en) | Antiallergic composition | |
| TWI465565B (en) | Fermentated foods containing bacteria of the genus bifidobacterium and method of preparing the same | |
| JP5274525B2 (en) | Whitening composition and cosmetics containing these | |
| CN105733983B (en) | Isolated microbial strains lactobacillus gasseri MCC2 DSM 23882 and application thereof | |
| KR102287584B1 (en) | Composition comprising Lactobacillus sakei derived from Lonicera japonica Thunb. or cultured products thereof as a active ingredient | |
| WO2018155660A1 (en) | Composition containing dead cell bodies of lactic acid bacterium or treated product thereof, and cosmetic, household good, drug or food containing said composition | |
| HUE032690T2 (en) | Fermented soy-based mixture comprising isoflavones-aglycones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields | |
| CN113604395B (en) | Lactobacillus plantarum capable of fermenting dendrobium nobile and improving skin quality by fermentation liquor thereof | |
| CN106212675A (en) | A kind of tea flavour flavored fermented milk and preparation method thereof | |
| JP5270680B2 (en) | Soybean fermented polymer substance mixed with folic acid and composition containing the same | |
| EP1790715A1 (en) | Method for stabilizing the antiallergic activity of lactic acid bacteria aganst high-temperature treatment, stabilized compositions, and food and drink | |
| AU2009220403B2 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
| CN110269889A (en) | Probiotics and its preparation method and application | |
| KR101341263B1 (en) | Method for manufacturing fermented turmeric using a probiotic strain, Lactobacills johnsonii IDCC 9203 | |
| US20090196867A1 (en) | Soy kefir powder and uses thereof | |
| TWI679982B (en) | Use of lactic acid bacteria fermented material for producing inhibitor of pentosine | |
| JP2018012681A (en) | Oral composition | |
| JP2008222701A (en) | Fermented product for preventing and treating obesity, fermented product for preventing diabetes, fermented food for preventing and treating obesity and food for preventing diabetes | |
| JP4644771B2 (en) | Sugar cane lactic acid fermented beverage and method for producing the same | |
| JP4841718B2 (en) | Antiallergic and antioxidants | |
| JP2008245545A (en) | Method for producing fermented sesame, and the fermented sesame | |
| JP2014141462A (en) | Peptide, and angiotensin converting enzyme inhibitor, antihypertensive agent, and food and drink product | |
| KR102080324B1 (en) | Rice yogurts and manufacturing method thereof | |
| JP2003259860A (en) | Lactococcus lactis cbt-19, method for producing separated concentrate of antibacterial cultured liquid by using the same and cosmetic composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100903 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101109 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101124 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131203 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4637491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |